MRI-PDFF脂肪下降50%与30%对MASH纤维化改善的预测价值
该研究为一项随机安慰剂对照试验的二次分析,纳入163例活检确诊的MASH伴2或3期纤维化患者,接受pegozafermin或安慰剂治疗24周。两者均显著预测MASH缓解不伴纤维化恶化。
要点
- MRI-PDFF超级应答(≥50%下降)独立预测纤维化改善不伴MASH恶化。
- MRI-PDFF应答(≥30%下降)对纤维化改善的预测未达统计学显著。
- 超级应答与应答均显著预测MASH缓解不伴纤维化恶化。
核心结论
- MRI-PDFF超级应答可预测纤维化回归不伴MASH恶化,且较MRI-PDFF应答更可能预测MASH缓解不伴纤维化恶化。
研究设计与样本
- 一项大规模多中心随机安慰剂对照试验的二次分析,纳入163例活检确诊的MASH伴2或3期纤维化患者,接受pegozafermin或安慰剂治疗24周。
关键数值与推荐
- MRI-PDFF超级应答定义为MRI-PDFF肝脏脂肪含量相对下降≥50%。
- MRI-PDFF应答定义为MRI-PDFF肝脏脂肪含量相对下降≥30%。
临床怎么用
- 在MASH伴2或3期纤维化患者中,MRI-PDFF脂肪下降≥50%可提示纤维化改善可能,支持用于治疗监测。
- MRI-PDFF脂肪下降≥30%对纤维化改善的预测价值有限,不应单独作为纤维化改善的替代指标。
局限性
- 本研究为随机对照试验的二次分析,结果需在前瞻性研究中验证。
- 研究仅纳入活检确诊的MASH伴2或3期纤维化患者,结论外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) response (≥30% relative decline in liver fat content on MRI-PDFF) can help to detect resolution of metabolic dysfunction-associated steatohepatitis (MASH) resolution, but there are limited data on whether it can reliably predict fibrosis improvement. We examined the association between MRI-PDFF super response (≥50% relative decline in liver fat content on MRI-PDFF) and fibrosis regression in a randomized placebo-controlled trial. METHODS: This is a secondary analysis of a large, multi-center, randomized, placebo-controlled trial that included 163 participants (64% female) with biopsy-confirmed MASH with stage 2 or 3 fibrosis who were treated for 24 weeks with pegozafermin or placebo and underwent contemporaneous laboratory testing, MRI-PDFF, and liver biopsy at 2 time points. The co-primary outcomes were fibrosis improvement without worsening of MASH and MASH resolution with no worsening of fibrosis. RESULTS: The median age and body mass index (BMI) of participants were 56.0 years (interquartile range, 48.0-62.0 years) and 36.5 kg/m2 (interquartile range, 32.2-40.2 kg/m2). The proportion of patients who achieved super-response was significantly higher in participants treated with pegozafermin (pooled 15 mg, 30 mg, and 44 mg arms) vs placebo (57.8% vs 11.1%; P < .0001). After multivariable adjustment for age, sex, BMI, race/ethnicity, and type 2 diabetes, MRI-PDFF super-response (adjusted odds ratio, 3.08; 95% confidence interval, 1.32-7.19; P = .009) remained an independent predictor of fibrosis regression without worsening MASH, but not MRI-PDFF response (adjusted odds ratio, 2.10; 95% confidence interval, 0.85-5.16; P = .11). Both MRI-PDFF response (P = .004) and MRI-PDFF super response (P < .001) were significant predictors of MASH resolution without worsening fibrosis. CONCLUSIONS: MRI-PDFF super response predicts fibrosis regression without worsening MASH, and a greater likelihood of MASH resolution without worsening fibrosis than MRI-PDFF response.
引用
- Loomba R, Daniel PCN, Wang Y, et al. Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-Associated Steatohepatitis. Clin Gastroenterol Hepatol. 2026. PMID: 41655805. doi:10.1016/j.cgh.2026.01.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。